NCT01807182View on ClinicalTrials.gov

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 20, 2013

Primary Completion Date

August 26, 2021

Study Completion Date

August 26, 2021

Conditions

Stage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7Metastatic Melanoma

Interventions

BIOLOGICAL

Aldesleukin

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Therapeutic Tumor Infiltrating Lymphocytes

Undergo TIL infusion

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT01807182 - Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter